De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

ICON Toekomstige groei

Future criteriumcontroles 1/6

ICON zal naar verwachting groeien in winst en omzet met respectievelijk 14.4% en 6.7% per jaar. De winst per aandeel zal naar verwachting groeien met 15.8% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 13.5% zijn.

Belangrijke informatie

14.4%

Groei van de winst

15.8%

Groei van de winst per aandeel

Life Sciences winstgroei	17.5%
Inkomstengroei	6.7%
Toekomstig rendement op eigen vermogen	13.5%
Dekking van analisten	Good
Laatst bijgewerkt	02 Oct 2024

Recente toekomstige groei-updates

ICON Public Limited Company Just Recorded A 8.9% EPS Beat: Here's What Analysts Are Forecasting Next

Apr 28

Recent updates

An Intrinsic Calculation For ICON Public Limited Company (NASDAQ:ICLR) Suggests It's 28% Undervalued

Aug 10

ICON: Deleveraging Complete, Now See 18% CAGR In Valuation To FY'26E (Rating Upgrade)

Jul 13

Earnings Tell The Story For ICON Public Limited Company (NASDAQ:ICLR)

Jun 14

Here's Why We Think ICON (NASDAQ:ICLR) Is Well Worth Watching

May 30

ICON (NASDAQ:ICLR) Has A Pretty Healthy Balance Sheet

May 14

ICON Public Limited Company Just Recorded A 8.9% EPS Beat: Here's What Analysts Are Forecasting Next

Apr 28

What Does ICON Public Limited Company's (NASDAQ:ICLR) Share Price Indicate?

Apr 21

ICON Public Limited Company's (NASDAQ:ICLR) Intrinsic Value Is Potentially 33% Above Its Share Price

Apr 05

ICON Public Limited Company (NASDAQ:ICLR) Looks Just Right With A 27% Price Jump

Mar 05

With EPS Growth And More, ICON (NASDAQ:ICLR) Makes An Interesting Case

Feb 07

ICON: Will The Huge Acquisition Of PRA Continue To Create Synergies?

Feb 01

These 4 Measures Indicate That ICON (NASDAQ:ICLR) Is Using Debt Reasonably Well

Jan 23

Is It Too Late To Consider Buying ICON Public Limited Company (NASDAQ:ICLR)?

Jan 08

What You Can Learn From ICON Public Limited Company's (NASDAQ:ICLR) P/E

Dec 24

A Look At The Fair Value Of ICON Public Limited Company (NASDAQ:ICLR)

Dec 09

With EPS Growth And More, ICON (NASDAQ:ICLR) Makes An Interesting Case

Nov 08

Why ICON Public Limited Company (NASDAQ:ICLR) Could Be Worth Watching

Oct 09

Is ICON (NASDAQ:ICLR) Using Too Much Debt?

Sep 23

Calculating The Fair Value Of ICON Public Limited Company (NASDAQ:ICLR)

Sep 05

Does ICON (NASDAQ:ICLR) Deserve A Spot On Your Watchlist?

Aug 03

Is It Too Late To Consider Buying ICON Public Limited Company (NASDAQ:ICLR)?

Jun 30

Is ICON (NASDAQ:ICLR) Using Too Much Debt?

Jun 12

Calculating The Fair Value Of ICON Public Limited Company (NASDAQ:ICLR)

May 23

Should You Think About Buying ICON Public Limited Company (NASDAQ:ICLR) Now?

Mar 29

Is ICON (NASDAQ:ICLR) Using Too Much Debt?

Mar 11

Are Investors Undervaluing ICON Public Limited Company (NASDAQ:ICLR) By 28%?

Feb 21

Why ICON Public Limited Company (NASDAQ:ICLR) Could Be Worth Watching

Dec 28

These 4 Measures Indicate That ICON (NASDAQ:ICLR) Is Using Debt Reasonably Well

Dec 10

Is ICON Public Limited Company (NASDAQ:ICLR) Trading At A 26% Discount?

Nov 22

Icon selected by BARDA to conduct anthrax vaccine clinical trial

Oct 06

Is ICON Public Limited Company (NASDAQ:ICLR) Potentially Undervalued?

Sep 15

ICON (NASDAQ:ICLR) Seems To Use Debt Quite Sensibly

Aug 26

Baron Funds - ICON Plc: Positioned For An Extended Period Of Revenue And Earnings Growth

Aug 11

Are Investors Undervaluing ICON Public Limited Company (NASDAQ:ICLR) By 41%?

Aug 01

Icon Q2 2022 Earnings Preview

Jul 26

ICON (NASDAQ:ICLR) Has A Pretty Healthy Balance Sheet

May 11

Winst- en omzetgroeiprognoses

NasdaqGS:ICLR - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	9,848	1,090	1,494	1,742	12
12/31/2025	9,205	949	1,396	1,504	16
12/31/2024	8,511	761	1,182	1,284	16
6/30/2024	8,332	714	1,182	1,327	N/A
3/31/2024	8,232	683	1,172	1,313	N/A
12/31/2023	8,120	612	1,020	1,161	N/A
9/30/2023	8,016	513	516	661	N/A
6/30/2023	7,903	510	381	534	N/A
3/31/2023	7,818	510	363	512	N/A
12/31/2022	7,741	505	421	563	N/A
9/30/2022	7,665	464	780	913	N/A
6/30/2022	7,588	210	878	998	N/A
3/31/2022	6,524	168	839	944	N/A
12/31/2021	5,481	153	735	829	N/A
9/30/2021	4,356	178	676	735	N/A
6/30/2021	3,191	364	506	548	N/A
3/31/2021	2,940	338	499	537	N/A
12/31/2020	2,797	328	527	568	N/A
9/30/2020	2,762	322	460	507	N/A
6/30/2020	2,771	324	502	556	N/A
3/31/2020	2,846	368	406	461	N/A
12/31/2019	2,806	369	374	413	N/A
9/30/2019	2,759	362	287	339	N/A
6/30/2019	2,704	353	257	306	N/A
3/31/2019	2,651	333	276	323	N/A
12/31/2018	2,596	323	220	269	N/A
9/30/2018	2,372	306	264	314	N/A
6/30/2018	2,157	295	248	294	N/A
3/31/2018	1,947	288	N/A	264	N/A
12/31/2017	1,758	281	N/A	383	N/A
9/30/2017	1,738	285	N/A	407	N/A
6/30/2017	1,718	274	N/A	350	N/A
3/31/2017	1,698	271	N/A	359	N/A
12/31/2016	1,666	262	N/A	259	N/A
9/30/2016	1,635	251	N/A	245	N/A
6/30/2016	1,609	249	N/A	267	N/A
3/31/2016	1,587	247	N/A	277	N/A
12/31/2015	1,575	240	N/A	279	N/A
9/30/2015	1,562	221	N/A	239	N/A
6/30/2015	1,555	210	N/A	275	N/A
3/31/2015	1,542	192	N/A	192	N/A
12/31/2014	1,503	172	N/A	169	N/A
9/30/2014	1,458	161	N/A	192	N/A
6/30/2014	1,411	138	N/A	125	N/A
3/31/2014	1,369	120	N/A	191	N/A
12/31/2013	1,336	103	N/A	221	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei ICLR ( 14.4% per jaar) ligt boven de spaarquote ( 2.5% ).

Winst versus markt: De winst van ICLR ( 14.4% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 15.2% per jaar).

Hoge groeiwinsten: De winst van ICLR zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van ICLR ( 6.7% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 8.7% per jaar).

Hoge groei-inkomsten: De omzet van ICLR ( 6.7% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen ICLR zal naar verwachting over 3 jaar laag zijn ( 13.5 %).

ICON Toekomstige groei

Future criteriumcontroles 1/6

Belangrijke informatie

Recente toekomstige groei-updates

ICON Public Limited Company Updates Earnings Guidance for the Full-Year 2024

ICON Public Limited Company Reaffirms Earnings Guidance for the Year 2024

ICON Public Limited Company Just Recorded A 8.9% EPS Beat: Here's What Analysts Are Forecasting Next

Price target increased by 13% to US$349

ICON Public Limited Company Reaffirms Earnings Guidance for the Full Year 2024

ICON Public Limited Company Provides Earnings Guidance for the Full Year 2023 and 2024

Recent updates

ICON Public Limited Company to Report Q3, 2024 Results on Oct 23, 2024

Here's Why ICON (NASDAQ:ICLR) Has Caught The Eye Of Investors

Should You Think About Buying ICON Public Limited Company (NASDAQ:ICLR) Now?

We Think ICON (NASDAQ:ICLR) Can Stay On Top Of Its Debt

ICON plc Announces Chief Financial Officer Changes

An Intrinsic Calculation For ICON Public Limited Company (NASDAQ:ICLR) Suggests It's 28% Undervalued

Insufficient new directors

Chief Financial Officer notifies of intention to sell stock

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

ICON Public Limited Company Updates Earnings Guidance for the Full-Year 2024

ICON Public Limited Company Announces Board Changes

Now 21% undervalued

ICON: Deleveraging Complete, Now See 18% CAGR In Valuation To FY'26E (Rating Upgrade)

ICON Public Limited Company to Report Q2, 2024 Results on Jul 24, 2024

Earnings Tell The Story For ICON Public Limited Company (NASDAQ:ICLR)

ICON Public Limited Company, Annual General Meeting, Jul 23, 2024

Chief Administrative Officer notifies of intention to sell stock

ICON Public Limited Company Reaffirms Earnings Guidance for the Year 2024

Here's Why We Think ICON (NASDAQ:ICLR) Is Well Worth Watching

ICON (NASDAQ:ICLR) Has A Pretty Healthy Balance Sheet

ICON Public Limited Company Just Recorded A 8.9% EPS Beat: Here's What Analysts Are Forecasting Next

Now 20% undervalued

First quarter 2024 earnings: EPS exceeds analyst expectations

What Does ICON Public Limited Company's (NASDAQ:ICLR) Share Price Indicate?

ICON Public Limited Company's (NASDAQ:ICLR) Intrinsic Value Is Potentially 33% Above Its Share Price

Brendan Brennan to Resign as Chief Financial Officer of ICON Public Limited Company in Fourth Quarter 2024

Now 20% undervalued

ICON Public Limited Company to Report Q1, 2024 Results on Apr 24, 2024

Now 20% undervalued

ICON Public Limited Company (NASDAQ:ICLR) Looks Just Right With A 27% Price Jump

Price target increased by 13% to US$349

Full year 2023 earnings: EPS exceeds analyst expectations

ICON Public Limited Company Reaffirms Earnings Guidance for the Full Year 2024

With EPS Growth And More, ICON (NASDAQ:ICLR) Makes An Interesting Case

ICON: Will The Huge Acquisition Of PRA Continue To Create Synergies?

ICON Public Limited Company to Report Q4, 2023 Results on Feb 21, 2024

These 4 Measures Indicate That ICON (NASDAQ:ICLR) Is Using Debt Reasonably Well

ICON Public Limited Company Provides Earnings Guidance for the Full Year 2023 and 2024

Is It Too Late To Consider Buying ICON Public Limited Company (NASDAQ:ICLR)?

What You Can Learn From ICON Public Limited Company's (NASDAQ:ICLR) P/E

Board Member notifies of intention to sell stock

A Look At The Fair Value Of ICON Public Limited Company (NASDAQ:ICLR)

Chief Financial Officer notifies of intention to sell stock

With EPS Growth And More, ICON (NASDAQ:ICLR) Makes An Interesting Case

Third quarter 2023 earnings: Revenues and EPS in line with analyst expectations

ICON Public Limited Company (NasdaqGS:ICLR) acquired Philips Pharma Solutions.

Why ICON Public Limited Company (NASDAQ:ICLR) Could Be Worth Watching

Is ICON (NASDAQ:ICLR) Using Too Much Debt?

ICON Public Limited Company to Report Q3, 2023 Results on Oct 25, 2023

ICON plc Releases Expanded End-To-End Clinical Trial Tokenisation Solution

CEO & Director notifies of intention to sell stock

ICON plc Partners with the U.S. Biomedical Advanced Research and Development Authority to Execute Next Generation COVID-19 Vaccines Clinical Trial

Calculating The Fair Value Of ICON Public Limited Company (NASDAQ:ICLR)

Board Member notifies of intention to sell stock

Does ICON (NASDAQ:ICLR) Deserve A Spot On Your Watchlist?

CEO & Director notifies of intention to sell stock

Price target increased by 7.6% to US$279

Second quarter 2023 earnings: EPS misses analyst expectations

Is It Too Late To Consider Buying ICON Public Limited Company (NASDAQ:ICLR)?

ICON Public Limited Company to Report Q2, 2023 Results on Jul 26, 2023

ICON Public Limited Company, Annual General Meeting, Jul 25, 2023

Is ICON (NASDAQ:ICLR) Using Too Much Debt?

Key Executive notifies of intention to sell stock

Calculating The Fair Value Of ICON Public Limited Company (NASDAQ:ICLR)

First quarter 2023 earnings: EPS misses analyst expectations

Now 20% undervalued after recent price drop

Should You Think About Buying ICON Public Limited Company (NASDAQ:ICLR) Now?

Is ICON (NASDAQ:ICLR) Using Too Much Debt?

Full year 2022 earnings: EPS misses analyst expectations